1. Introduction
In March 2017, nivolumab, an immune checkpoint inhibitor, was approved
for use in the treatment of squamous cell carcinomas of the head and
neck with recurrence or metastasis in Japan. Nivolumab differs from
conventional chemotherapeutic drugs, in that, it is known to show a
reaction and has been reported to be highly effective for lung cancer,
when given after immunotherapy; however, few reports of its use for
head and neck cancer treatment are
available. Here, we present our experience with a patient who had
recurrent cervical lymph node metastasis caused by tongue cancer.
Administration of cetuximab and nivolumab led to increased metastasis,
but readministration of cetuximab resulted in a remarkable response.